Evaluation of VQm PHM on Pulmonary Health Parameters for ICU
Launched by ROSTRUM MEDICAL INNOVATIONS INC. · Nov 24, 2023
Trial Information
Current as of November 07, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to measure lung health in patients who are in the Intensive Care Unit (ICU). The researchers want to see how well a device called VQm PHM™ performs when measuring important lung parameters, such as how well blood is flowing to the lungs and how much air is in the lungs. They will compare these measurements to standard methods currently used in hospitals to ensure they are accurate and reliable.
To participate in the trial, individuals must be at least 18 years old and currently admitted to the ICU, requiring specific monitoring for their heart and lungs. They should also be on a certain type of mechanical ventilation. Participants will need to give consent, either by themselves or through a trusted person. If someone is under 18, pregnant, or has certain medical conditions, they won't be eligible. This trial is not yet recruiting participants, but it aims to find better ways to monitor and improve lung health in critically ill patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female 18 years old or above, at the time of the inclusion
- • Patient currently admitted in the ICU, who are indicated for cardiac output monitoring using a pulmonary artery catheter and who require pressure or volume controlled mechanical ventilation using an ETT
- • Provision of signed and dated informed consent form (ICF) by the patient or a trusted person
- Exclusion Criteria:
- • Male or female under the age of 18 years old, at the time of screening
- • Patient under guardianship
- • Patient who requires tidal volumes of less than 250cc
- • Pregnancy
- • Patient whose care requires the use of an anesthetic conserving device
- • Patient whose care requires a closed-loop ventilator
- • Patient who is unable to tolerate a transient increase in inhaled CO2
- • Patient who is unable to tolerate a transient inhalation of N2O or is contraindicated to N2O use
About Rostrum Medical Innovations Inc.
Rostrum Medical Innovations Inc. is a forward-thinking clinical trial sponsor dedicated to advancing healthcare through innovative medical solutions. With a focus on developing cutting-edge therapies and technologies, the company collaborates with research institutions and healthcare professionals to conduct rigorous clinical trials that meet the highest standards of safety and efficacy. Leveraging a team of experienced scientists and regulatory experts, Rostrum Medical Innovations is committed to translating scientific breakthroughs into meaningful treatments that improve patient outcomes and enhance quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Sacramento, California, United States
Paris, France
Vienna, Austria
Prague, Czechia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported